Key result
Higher HDL-C linked to ~81% lower mortality and heart transplant risk in non-ischemic dilated cardiomyopathy.
Why the study?
The specific prognostic role of HDL-C levels in patients with non-ischemic dilated cardiomyopathy remains undefined.
Are lower HDL-C levels associated with an increased risk of adverse outcomes in patients with non-ischemic dilated cardiomyopathy?
Cohort (n=297)
No
Are lower HDL-C levels associated with an increased risk of adverse outcomes in patients with non-ischemic dilated cardiomyopathy?
Lower HDL-C levels are an independent prognostic biomarker associated with increased risk of mortality and heart transplantation in patients with non-ischemic dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May refine risk stratification in non-ischemic dilated cardiomyopathy; hypothesis-generating for HDL-C modulation.
Background: Although low high-density lipoprotein cholesterol (HDL-C) is associated with poor outcomes in heart failure, its specific prognostic role in non-ischemic dilated cardiomyopathy (DCM) remains undefined. This study aimed to investigate the association between HDL-C levels and long-term clinical outcomes in patients with DCM. Methods: We retrospectively enrolled 297 patients with DCM who underwent cardiac magnetic resonance between January 2017 and October 2024. The primary endpoint was a composite of all-cause mortality and heart transplantation; the secondary endpoint additionally included heart failure readmission. The associations between HDL-C and clinical outcomes were assessed using Kaplan-Meier analysis, Cox regression, restricted cubic spline (RCS), and sensitivity analyses. Results: During a median follow-up of 35 months, 41 (13.8%) and 97 (32.7%) patients experienced the primary and secondary endpoints, respectively. Kaplan-Meier analysis demonstrated that patients with higher HDL-C had significantly better event-free survival for both the primary and secondary endpoints (log-rank P < 0.001 for both). In multivariable Cox regression models, lower HDL-C was consistently and independently associated with an increased risk of the primary (hazard ratio [HR] 0.19, 95% confidence interval [CI]: 0.05-0.68, P = 0.011) and secondary (HR 0.15, 95% CI: 0.07-0.34, P < 0.001) endpoints. After further adjustment for echocardiographically estimated pulmonary artery systolic pressure, the effect estimate for the association between HDL-C and clinical outcomes was attenuated (primary endpoint: HR 0.31, 95% CI: 0.08-1.11, P = 0.072; secondary endpoint: HR 0.19, 95% CI: 0.08-0.44, P < 0.001). RCS curves showed a linear relationship between HDL-C and both endpoints (P for nonlinearity > 0.05 for both). Sensitivity analyses confirmed the robustness of the results. Conclusions: Lower HDL-C levels were independently associated with adverse outcomes in patients with non-ischemic DCM, an association partly attenuated by adjusting for pulmonary hypertension markers. As a readily available prognostic biomarker, HDL-C may inform risk stratification in this population.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2026) conducted a cohort in Non-ischemic dilated cardiomyopathy (n=297). High-density lipoprotein cholesterol (HDL-C) vs. Lower HDL-C levels was evaluated on Composite of all-cause mortality and heart transplantation (HR 0.19, 95% CI 0.05-0.68, p=0.011). Higher HDL-C levels were independently associated with a reduced risk of all-cause mortality and heart transplantation in patients with non-ischemic dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: